+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)

  • PDF Icon


  • June 2021
  • Region: Global
  • GlobalData
  • ID: 5134535
ALK Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on ALK Tests market for the year 2020 and beyond. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. Secondary sources estimate that approximately 2.0 million new cases of lung cancer were reported worldwide in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

ALK is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation and differentiation. ALK gene rearrangements account for 5-6% of NSCLC cases. The majority of ALK mutations are translocations, whereby the ALK gene is partnered with other gene to form a fusion oncogene. Different ALK fusion partners have been identified in NSCLC cases, including EML4, KIF5B, KLC1, and TPR. NSCLC patients with ALK rearrangements are eligible for ALK tyrosine kinase inhibitor (TKI) therapy.

ALK Tests model include ALT Immunohistochemistry (IHC) Tests, ALK In Situ Hybridization (ISH) Tests and ALK Nucleic Acid Amplification Tests (NAATs).

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed ALK Tests and evolving competitive landscape -
  • Insightful review of the key industry trends.
  • Annualized total ALK Tests market revenue by segment and market outlooks from 2015-2030.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, the publisher analysts provide unique country specific insights on the market.
  • SWOT analysis for ALK Tests market.
  • Competitive dynamics insights and trends provided for ALK Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Abbott Laboratories, ZytoVision GmbH, Leica Biosystems Nussloch GmbH, Qiagen NV, Roche Diagnostics International Ltd, Agilent Technologies Inc, Cytocell Ltd, Thermo Fisher Scientific Inc, MilliporeSigma, Takara Bio Inc, Biocare Medical LLC, Amoy Diagnostics Co Ltd, Panagene Inc, Other,

Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


Who should buy this report?

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the ALK Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -
  • Understand the impact of COVID-19 on ALK Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving ALK Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALK Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific ALK Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • ZytoVision GmbH
  • Leica Biosystems Nussloch GmbH
  • Qiagen NV
  • Roche Diagnostics International Ltd
  • Agilent Technologies Inc
  • Cytocell Ltd
  • Thermo Fisher Scientific Inc
  • MilliporeSigma
  • Takara Bio Inc
  • Biocare Medical LLC
  • Amoy Diagnostics Co Ltd
  • Panagene Inc